Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS’ Abilify Label Adds More Bipolars

This article was originally published in The Pink Sheet Daily

Executive Summary

Maintenance in pediatrics, teens made official by FDA.

You may also be interested in...



Antipsychotic Not Certain Savior For Forest

Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.

Antipsychotic Not Certain Savior For Forest

Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.

Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10

Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel